Acid reflux, heartburn, peptic ulcer disease, and erosive oesophagitis are among the most common chronic conditions worldwide — affecting 10–30% of adults in Western populations and a similar fraction across South and East Asia. Modern acid-related disease is highly treatable: gastric pH can be raised reliably and safely with widely available oral medicines, and the underlying causes (Helicobacter pylori infection, NSAID-induced injury, lifestyle factors, hiatus hernia) can be diagnosed and addressed. The acid-reflux category at MedsBase covers all three drug classes used for these conditions plus mucosal protectants and chewable antacids — 26 products from WHO-GMP certified manufacturers.
Proton-pump inhibitors (PPIs) are the most potent acid-suppressing class and the first-line treatment for moderate-to-severe GERD, erosive oesophagitis, peptic ulcer healing, NSAID ulcer prophylaxis, and Helicobacter pylori eradication regimens. They work by irreversibly blocking the H+/K+-ATPase proton pump in stomach parietal cells. Six PPI molecules are stocked: omeprazole (Omeeforce, Omeford, Omesec, Omez, Omez 20 — the original PPI, OTC standard worldwide), esomeprazole (Esoprol, Neksium, Nexpro — the S-isomer of omeprazole with 30% AUC advantage and faster healing of severe erosive disease), pantoprazole (Pan, Pantodac, Pentab, Penlip, Walapan-40 — the cleanest drug-interaction profile of the class, preferred for clopidogrel users and complex polypharmacy), lansoprazole (Lan, Lanzol, Pepzol — faster onset on day one), rabeprazole (Rabium, Razo — partial non-enzymatic activation, less CYP2C19 dependence), and ilaprazole (Ilapro — long half-life ~9 hours for sustained 24-hour acid suppression).
Pantocid Injection is intravenous pantoprazole 40 mg per vial for hospital use — used in upper-GI bleed (80 mg bolus + 8 mg/h infusion × 72 hours after endoscopic haemostasis), in NPO patients, and for ICU stress-ulcer prophylaxis. Pantocid DSR combines pantoprazole 40 mg with domperidone 30 mg sustained-release in a single capsule — useful where motility is the dominant problem (GERD with regurgitation, gastroparesis, post-prandial fullness), with mandatory cardiac safety considerations because of domperidone’s QT-interval signal.
Histamine H2 receptor antagonists reduce acid secretion at a different point in the parietal-cell signalling pathway. They act faster than PPIs (within 30 minutes) but the maximum suppression is shallower and tachyphylaxis develops after 7–14 days of continuous use. Famocid (famotidine 20/40 mg by Sun Pharma) is the modern preferred H2 antagonist — useful for on-demand mild GERD, breakthrough symptoms on PPI (especially nocturnal), NSAID ulcer prophylaxis, and pregnancy reflux. Famotidine is the recommended substitute for ranitidine, which was withdrawn from US, EU, UK and Canadian markets in 2020 over N-nitrosodimethylamine (NDMA) carcinogen contamination. Aciloc (ranitidine 150/300 mg by Cadila) and Rantac 300 (ranitidine 300 mg) remain available in the Indian market — the Indian regulator CDSCO did not formally withdraw — but every product page carries an explicit NDMA warning and recommends switching to famotidine.
Mucosal protectants and antacids work locally and complement acid suppression rather than replacing it. Macralfate Suspension is sucralfate 1 g per 10 mL — an aluminium-sucrose-octasulfate complex that polymerises in stomach acid and physically coats ulcers, promoting healing. Useful for peptic ulcer disease, bile-reflux gastritis (where PPIs help less), NSAID gastritis, radiation oesophagitis, and chemotherapy oral mucositis. Acigene is a chewable antacid combining aluminium hydroxide + magnesium hydroxide + simethicone + magnesium aluminium silicate — for breakthrough symptoms and as bridging therapy while a PPI is reaching full effect. Antacids work within minutes but last only 30–60 minutes.
Hoe te kiezen: For chronic moderate-to-severe reflux, peptic ulcer disease, erosive oesophagitis, or H. pylori eradication, a PPI is first-line — choose pantoprazole (Pan, Pantodac, Walapan-40) if drug interactions matter, esomeprazole (Esoprol, Neksium, Nexpro) for severe erosive disease, omeprazole (Omez, Omesec) as the well-priced workhorse, ilaprazole (Ilapro) for nocturnal acid breakthrough on standard PPIs, and rabeprazole (Razo, Rabium) for CYP2C19 poor metabolisers. For mild on-demand reflux or breakthrough symptoms on PPI, famotidine (Famocid) is the H2 antagonist of choice. For peptic ulcer healing where mucosal coating helps and bile-reflux gastritis, add sucralfate (Macralfate). For occasional after-meal heartburn or to bridge while a PPI takes effect, an antacid (Acigene) gives the fastest relief. Alarm symptoms — unexplained weight loss, difficulty swallowing, vomiting blood, dark/tarry stools, anaemia, age over 55 with new-onset reflux symptoms — require investigation, not empirical acid-suppressive therapy.
All 26 products are dispatched from WHO-GMP certified manufacturers (Sun Pharma, Cipla, Dr. Reddy’s, AstraZeneca India, Torrent, Zydus Cadila, Alkem, Intas, JB Chemicals, and others). Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within the expected window, we reship it free.
Koopgids 2026: Bekijk onze selectie Best Acid Reflux Medications 2026 voor gerangschikte keuzes, vergelijkingstabel, doseringsadviezen en beslissingshulp.